Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised … GD Demetri, P Reichardt, YK Kang, JY Blay, P Rutkowski, H Gelderblom, ... The Lancet 381 (9863), 295-302, 2013 | 1497 | 2013 |
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial H Joensuu, M Eriksson, KS Hall, JT Hartmann, D Pink, J Schütte, ... Jama 307 (12), 1265-1272, 2012 | 1168 | 2012 |
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv51-iv67, 2018 | 888 | 2018 |
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial P Schöffski, S Chawla, RG Maki, A Italiano, H Gelderblom, E Choy, ... The Lancet 387 (10028), 1629-1637, 2016 | 783 | 2016 |
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv68-iv78, 2018 | 587 | 2018 |
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, S Bielack, N Abecassis, HT Aro, S Bauer, R Biagini, ... Annals of Oncology 29, iv79-iv95, 2018 | 535 | 2018 |
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ A Gronchi, AB Miah, AP Dei Tos, N Abecassis, J Bajpai, S Bauer, ... Annals of Oncology 32 (11), 1348-1365, 2021 | 519 | 2021 |
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors G Antoch, J Kanja, S Bauer, H Kuehl, K Renzing-Koehler, J Schuette, ... Journal of Nuclear Medicine 45 (3), 357-365, 2004 | 435 | 2004 |
An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between sarcoma PAtients EuroNet (SPAEN) and European organization for … B Kasper, C Baumgarten, J Garcia, S Bonvalot, R Haas, F Haller, ... Annals of Oncology 28 (10), 2399-2408, 2017 | 395 | 2017 |
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial JY Blay, C Serrano, MC Heinrich, J Zalcberg, S Bauer, H Gelderblom, ... The Lancet Oncology 21 (7), 923-934, 2020 | 338 | 2020 |
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial WD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ... The Lancet 394 (10197), 478-487, 2019 | 337 | 2019 |
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor S Bauer, LK Yu, GD Demetri, JA Fletcher Cancer research 66 (18), 9153-9161, 2006 | 328 | 2006 |
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway S Bauer, A Duensing, GD Demetri, JA Fletcher Oncogene 26 (54), 7560-7568, 2007 | 320 | 2007 |
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience P Rutkowski, A Gronchi, P Hohenberger, S Bonvalot, P Schöffski, S Bauer, ... Annals of surgical oncology 20, 2937-2943, 2013 | 285 | 2013 |
Narrow Window in Nanoscale Dependent Activation of Endothelial Cell Growth and Differentiation on TiO2 Nanotube Surfaces J Park, S Bauer, P Schmuki, K Von Der Mark Nano letters 9 (9), 3157-3164, 2009 | 282 | 2009 |
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, JY Blay, N Abecassis, J Bajpai, S Bauer, R Biagini, S Bielack, ... Annals of oncology 33 (1), 20-33, 2022 | 277 | 2022 |
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial MC Heinrich, RL Jones, M von Mehren, P Schöffski, C Serrano, YK Kang, ... The Lancet Oncology 21 (7), 935-946, 2020 | 265 | 2020 |
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes P Schöffski, IL Ray-Coquard, A Cioffi, NB Bui, S Bauer, JT Hartmann, ... The lancet oncology 12 (11), 1045-1052, 2011 | 244 | 2011 |
Integrative genomic and transcriptomic analysis of leiomyosarcoma P Chudasama, SS Mughal, MA Sanders, D Hübschmann, I Chung, ... Nature communications 9 (1), 144, 2018 | 240 | 2018 |
Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial H Joensuu, M Eriksson, K Sundby Hall, A Reichardt, JT Hartmann, D Pink, ... Journal of Clinical Oncology 34 (3), 244-250, 2016 | 236 | 2016 |